克拉德里宾用于患有多发性硬化症的人.
Maria Grazia Celani1, Massimiliano Orso2, Marta Melis3
1Dpt of Neurophysiopathology, Perugia General Hospital, Perugia, Italy.
The Cochrane database of systematic reviews
|January 9, 2026
概括
克拉德里宾可能会减少复发,并可能减少多发性硬化症 (MS) 的MRI病变,但其对残疾进展的影响尚不确定. 需要进一步的研究来确认益处和安全性.
科学领域:
- 神经科学和免疫学 神经科学和免疫学
- 药理学和治疗学 药理学和治疗学
背景情况:
- 多发性硬化症 (MS) 是一种由T和B细胞炎症驱动的慢性,自身免疫性中枢神经系统疾病.
- 克拉德里宾向淋巴细胞枯竭,以减少炎症并可能减缓多发性硬化症的进展.
研究的目的:
- 评估克拉迪宾与安慰剂,无干预或多发性硬化症 (MS) 其他疾病修饰药物的短期和长期疗效和安全性.
- 评估克拉迪宾对残疾恶化,疾病活性 (NEDA),复发和不良事件的影响.
主要方法:
- 系统性审查包括随机对照试验 (RCT),开放式扩展 (OLE) 和干预的非随机研究 (NRSI).
- 搜索了多个数据库,直到2025年2月,寻找MS中克拉迪宾的研究.
- 用于计算95%置信区间 (CI) 的风险比率 (RRs) 的元分析;使用GRADE评估的证据确定性.
主要成果:
- 克拉德里宾可能会减少新的复发 (中等确定性),并可能减少新的Gd+ T1MRI病变 (非常不确定的证据).
- 证据表明,对严重不良事件,残疾恶化或治疗中止的影响很小或不存在,确定性非常不确定.
- 观察性研究表明,相比于二甲基烟酸盐,特里弗卢诺米德和芬戈利莫德,克拉德里宾可能会减少复发,但证据往往非常不确定.
结论:
- 克拉迪宾,一种口服的MS治疗,可能会减少复发,并可能减少MRI病变,但对残疾进展产生不确定的影响.
- 长期数据表明,四年后可能会增加无疾病活动证据 (NEDA).
- 需要进一步进行高质量的试验和注册,以加强对克拉迪宾益处和安全性概况的证据基础.
更多相关视频
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
478
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
478
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
425
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
425
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
480
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
480
Myasthenia Gravis: Overview and Treatment
2.8K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.8K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Drugs for Treatment of Ulcerative Colitis in IBD
449
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
449


